The Genomic Editing and Screening (GES) Core was established in 2012 with institutional funds. Initially, it provided cutting-edge RNA interference (RNAi) gene target knockdown technologies toward the discovery of novel cancer targets and elucidation of complex aberrant intracellular pathways. A central feature is the use of third generation Pol II-driven, enhanced Mir30-based shRNA for high functional protein knockdown efficiency at single-copy integration, using a diverse panel of packaged retro-and lentiviral plasmid backbones for effective delivery. Establishment of this platform subsequently allowed for the rollout in 2014 of CRISPR-Cas9 sgRNA single-gene and full-genome knockout technologies via pooled libraries. Realization that many cell types are easily transfectable and that discrete intracellular events such as activation, translocation, and cell- to-cell communication can be quantified using high-speed automated fluorescence microscopy, the Core initiated high content imaging and analysis (HCA) for arrayed siRNA experimentation. A natural extension of this 96/384 well plate format was then evolved into a workstation-based small molecule compound screening program, allowing investigators to effectively phenocopy newly-identified targets using chemical biology approaches. The most promising of these compounds are then matriculated into the Early Therapeutics Center (ETC) and Tri-Institutional Therapeutic Drug Initiative (TRI-I TDI). Overall, this multi-modal Core enables mechanism-based science through target identification and drug screening, offering custom reagents and services to a growing number of the Center?s members.
| Mirpuri, Sheena; Gill, Pavan; Ocampo, Alex et al. (2018) Discrimination and Health Among Taxi Drivers in New York and Toronto. J Community Health 43:667-672 |
| Jones, Christopher W; Misemer, Benjamin S; Platts-Mills, Timothy F et al. (2018) Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study. BMJ Open 8:e019831 |
| Horvat, Natally; Ragucci, Monica; Mannelli, Lorenzo (2018) Hepatic Mass in a Patient With Bladder Cancer History. Gastroenterology 154:493-494 |
| Raghunathan, Nirupa Jaya; Benedict, Catherine; Thom, Bridgette et al. (2018) Young Adult Female Cancer Survivors' Concerns About Future Children's Health and Genetic Risk. J Adolesc Young Adult Oncol 7:125-129 |
| Arvold, Nils D; Armstrong, Terri S; Warren, Katherine E et al. (2018) Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro Oncol 20:897-906 |
| De, Brian; Cahlon, Oren; Sine, Kevin et al. (2018) Early Axial Growth Outcomes of Pediatric Patients Receiving Proton Craniospinal Irradiation. J Pediatr Hematol Oncol 40:574-579 |
| Chang, Kevin K; Yoon, Changhwan; Yi, Brendan C et al. (2018) Platelet-derived growth factor receptor-? and -? promote cancer stem cell phenotypes in sarcomas. Oncogenesis 7:47 |
| Dupnik, K M; Bean, J M; Lee, M H et al. (2018) Blood transcriptomic markers of Mycobacterium tuberculosis load in sputum. Int J Tuberc Lung Dis 22:950-958 |
| Roberts, Sheryl; Andreou, Chrysafis; Choi, Crystal et al. (2018) Sonophore-enhanced nanoemulsions for optoacoustic imaging of cancer. Chem Sci 9:5646-5657 |
| Romanoff, Anya; Zabor, Emily C; Petruolo, Oriana et al. (2018) Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers? Cancer 124:4314-4321 |
Showing the most recent 10 out of 8799 publications
